By hindering the interaction of CXCR4-positive tumor cells with CXCL12-producing fibroblasts, AMD3100 therapy in a pancreatic cancer model induced rapid T-cell accumulation among cancer cells and acted synergistically with anti-PD-L1 [133]. The gene discussed is CXCR4; the disease is pancreatic neoplasm.